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Abstract
The Cas scaffolding proteins (NEDD9/HEF1/CAS-L, BCAR1/p130Cas, EFSSIN, and HEPL/CASS4) regulate cell migration,
division and survival, and are often deregulated in cancer. High BCAR1 expression is linked to poor prognosis in breast
cancer patients, while upregulation of NEDD9 contributes to the metastatic behavior of melanoma and glioblastoma cells.
Our recent work knocking out the single Drosophila Cas protein, Dcas, identified a genetic interaction with E-cadherin. As E-
cadherin is often downregulated during epithelial-mesenchymal transition (EMT) prior to metastasis, if such an activity was
conserved in mammals it might partially explain how Cas proteins promote aggressive tumor behavior. We here establish
that Cas proteins negatively regulate E-cadherin expression in human mammary cells. Cas proteins do not affect E-cadherin
transcription, but rather, BCAR1 and NEDD9 signal through SRC to promote E-cadherin removal from the cell membrane
and lysosomal degradation. We also find mammary tumors arising in MMTV-polyoma virus T-antigen mice have enhanced
junctional E-cadherin in a Nedd9
2/2 background. Cumulatively, these results suggest a new role for Cas proteins in cell-cell
adhesion signaling in cancer.
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Introduction
The non-catalytic scaffolding proteins of the Cas family control
attachment, migration, cell cycle, and cell survival signaling
(reviewed in [1,2,3]) in mammalian cells. In vertebrates there are 4
family members: BCAR1/p130Cas [4], NEDD9/HEF1/Cas-L
[5], EFS/Sin [6] and CASS4/HEPL [7], of which BCAR1 and
NEDD9 have been the most intensively studied. A growing
number of studies have found that increased expression of Cas
proteins contributes to human tumor aggressiveness (reviewed in
[3,8]). BCAR1 overexpression confers invasiveness to cultured
cells, and promotes mammary tumorigenesis and lung metastasis
in the MMTV-HER2 and other mouse models of cancer [9,10].
BCAR1 overexpression also correlates with poor prognosis in
breast cancer patients [11,12]. NEDD9 overexpression is frequent
in glioblastomas [13], melanomas [14], and some lung cancers
[15], and promotes metastasis; upregulation of NEDD9 also
promotes oncogenic signaling in the hematopoietic system
[16,17,18,19,20], and supports invasive behavior in breast cancer
cell lines [21], while genetic ablation of NEDD9 limits mammary
tumor growth in the MMTV-polyomavirus middle T (PyVT)
model of tumorigenesis [22,23].
Tumor invasiveness often requires epithelial-mesenchymal
transition (EMT), during which cells lose lateral attachments to
their neighbors and become more motile. One of the hallmarks of
EMT is downregulation of the cell-cell adhesion protein
E-cadherin, resulting in destabilization of the adherens junctions
(AJs) that connect cells [24]. Mutations in E-cadherin, and
methylation of the E-cadherin promoter are described as common
causes of E-cadherin downregulation in human tumors, but are
not found in all tumors that have lost E-cadherin expression.
Another common mechanism for downregulation of E-cadherin in
EMT is transcriptional inhibition based on enhanced action of the
transcriptional repressors such as Snail or SLUG (reviewed in
[24]). Post-translationally, equilibrium expression of E-cadherin at
the plasma membrane is maintained by a regulated balance
between exocytosis and endocytosis [25]. Perturbation of this
balance can also results in E-cadherin removal from the plasma
membrane [25,26], providing an additional point of control for E-
cadherin downregulation in carcinomas.
Some recent results raise the possibility that Cas proteins might
influence E-cadherin expression. A 2008 clinical study of E-
cadherin and BCAR1 in hepatocellular carcinoma identified a
negative correlation between the expression of these two proteins
[27], while another work has demonstrated that the environmental
pollutant dioxin induces EMT through a pathway involving
NEDD9 [28]. The Cas proteins influence the activation of the
SRC and FAK kinases [7,22,29,30], and Rho GTPases [31,32],
which contribute to regulation of EMT-linked disassembly of E-
cadherin complexes at AJs (discussed in [33]). In a recent study by
our group, we found that genetic deletion of the single Cas family
member in Drosophila, Dcas, was synthetically lethal with
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catenin [34]. In embryos lacking Dcas, E-cadherin levels at lateral
cell contacts were significantly reduced during development,
although overall intracellular levels of E-cadherin were increased
[34]; these results suggested a defect in E-cadherin localization in
the absence of DCas caused signaling defects leading to a
paradoxical upregulation of E-cadherin. Based on these reports,
we investigated Cas protein regulation of E-cadherin in mammals.
We have found that NEDD9 and BCAR1 signal through SRC to
negatively regulate membrane localization of E-cadherin and its
interacting catenins, and in contrast to Drosophila, enhance the
lysosomal degradation of E-cadherin pools, leading to a net loss of
intracellular E-cadherin. These results suggest a new mechanism
by which overexpression of NEDD9 or BCAR1 may contribute to
aggressiveness in human tumors.
Results
Cas negatively regulates E-cadherin protein expression in
human cells
The MCF7 breast adenocarcinoma cell line has frequently been
used to study function of Cas proteins, and their activity in
promoting migration and invasion by these cells is well established
[21]. We used breast carcinoma MCF7 cells to overexpress
(Figure 1A) or siRNA-deplete (Figure 1B) BCAR1 and NEDD9,
individually or in combination, and monitored total expression of
E-cadherin and its partner proteins a-, b-, and p120catenin. E-
cadherin levels were downregulated in cells overexpressing
BCAR1 or NEDD9, and to a greater extent in cells ovexpressing
both proteins (Figures 1A, 1C). Reciprocally, and in contrast to
our results in Drosophila [34], E-cadherin protein accumulated in
cells with either NEDD9 or BCAR1 depleted, and to a higher level
in cells with both proteins depleted (Figures 1B, C). E-cadherin
associates with a-, b-, and p120catenin at cell junctions, and we
had previously identified genetic interactions between DCas and
the Drosophila orthologs of these proteins [34]. Extending this
analysis, we found that changes in Cas protein expression also
negatively regulated the expression of a-, b-, and p120catenin, but
to a lesser degree that that seen with E-cadherin (Figures 1A,B).
Cas proteins induce E-cadherin downregulation from cell
junctions and the detergent-insoluble cell fraction
E-cadherin protein expression might be negatively regulated by
Cas proteins via several possible mechanisms, including transcrip-
tional downregulation of E-cadherin expression. However,
quantitative RT-PCR analysis did not indicate any NEDD9- or
BCAR1-dependent changes in E-cadherin mRNA expression
(Figure 2A).
Alternatively, NEDD9 and BCAR1 may control association of
E-cadherin with the cell surface, which is associated with its rate of
degradation. Immunofluorescence analysis of E-cadherin in cells
where these proteins were depleted (Figure 2B) showed a thicker
band of of E-cadherin at points of cell-cell contact, particularly
when NEDD9 was depleted. Reciprocally, overexpression of these
proteins in combination resulted in a reduction in the levels of E-
cadherin and b-catenin detectable at cell junctions (Figure 2C,
2D). Interestingly, residual b-catenin staining was often detected
within intracellular compartments, colocalizing with overexpressed
NEDD9 and BCAR1 at focal adhesions (Figure 2D, E).
Subsequent cell fractionation analyses confirmed a specific
action of Cas proteins in negatively regulating the membrane- and
Figure 1. Cas proteins negatively regulate E-cadherin expression in MCF7 cells. A. Western analysis of MCF7 cells transfected with
plasmids including vector pcDNA-HA (-), pcDNA-HA-NEDD9 (N), pcDNA-HA-BCAR1 (B), or pcDNA-HA-NEDD9 and pcDNA-HA-BCAR1 (NB). B. Western
analysis of MCF7 transfected with siRNAs including scrambled control (scr), or targeting NEDD9 (siN), BCAR1 (siB) and both (siNB), probed with
antibodies indicated. C. Graph represents total levels of E-cadherin normalized to b-actin. *, P,0.01, **, P,0.001. Error bars represent SE. Additional
siRNA experiments (not shown) were performed with alternative siRNA oligonucleotides targeting NEDD9 and BCAR1: although knockdown was not
as efficient, qualitatively similar results were obtained in regard to E-cadherin expression.
doi:10.1371/journal.pone.0022102.g001
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E-cadherin is downregulated from the insoluble fraction in cells
overexpressing Cas proteins (2.5-fold in cells with both NEDD9
and BCAR1 depleted), and upregulated in Cas-depleted cultures
(2-fold in cells with both NEDD9 and BCAR1 overexpressed). By
contrast, the effect of increasing or decreasing Cas protein
expression on the levels of the soluble pool of cytoplasmic E-
cadherin did not rise to statistical significance (Figure 3B).
Cas proteins promote lysosomal degradation of
E-cadherin via SRC kinase
Upon endocytosis from the membrane, E-cadherin is either
recycled to the membrane or degraded in the lysosome.
Ammonium chloride, monensin and chloroquine each block
lysosomal activity [35]. Immunofluorescence analysis showed that
cells treated with cloroquine and overexpressing GFP-tagged
NEDD9 and BCAR1 together accumulated more E-cadherin in
vesicles marked with lysosomal marker LAMP-1 than control cells
overexpressing GFP alone (Figure 4A). Further, ammonium
chloride, monensin and chloroquine each effectively blocked the
E-cadherin degradation induced by Cas protein overexpression
(Figure 4B–E).
Activation of SRC causes internalization and lysosomal
degradation of E-cadherin [36,37,38], while Rho GTPases
destabilize adherens junctions by regulating actin polymerization
[39] or redistributing E-cadherin on the plasma membrane [40].
Both SRC and RhoA have been directly or functionally linked to
Cas proteins [32,41]. Using dasatinib or PP2 to inhibit SRC kinase
(Figures 5A–C), we established that inhibition of Src completely
blocked Cas-dependent E-cadherin degradation. In contrast,
inhibition of RhoA using Y-27632, a cell-permeable inhibitor of
the RhoA effector p160ROCK (Figure 5D, E), had a more limited
effect, which did not reach statistical significance if both NEDD9
and BCAR1 were overexpressed. We also found that in addition to
reversing loss of the insoluble pools of E-cadherin, treatment with
Src inhibitors restored E-cadherin to cell junctions in Cas-
overexpressing cells (Figure 6). Together, these results imply that
Cas activation of SRC signaling is most important for E-cadherin
internalization and degradation.
MMTV-PyVT tumors arising in a Nedd9
2/2 background
have increased E-cadherin at cell junctions
We have reported a longer latency until appearance of
mammary tumors in MMTV-PyVT mice, and depressed
activation of SRC, in the context of a Nedd9
2/2 versus a
Nedd9
+/+ genotype [22]. We find that loss of Nedd9 protein also
caused a noticeable change in the localization of E-cadherin in
tumors, with a much more intensive junctional staining pattern
consistently observed in Nedd9
2/2 tumors, versus a more
cytoplasmic distribution in Nedd9
+/+ tumors (Figure 7A). A similar
Figure 2. Cas proteins negatively regulate association of E-cadherin with cell junctions. A. qRT-PCR of mRNA isolated from MCF7 cells
transfected with plasmids including vector pcDNA-HA (-), pcDNA-HA-NEDD9 (N), pcDNA-HA-BCAR1 (B), or pcDNA-HA-NEDD9 and pcDNA-HA-BCAR1
(NB). B. MCF7 transfected with siRNAs including scrambled control (SCR), or targeting NEDD9 (siN), BCAR1 (siB) and both (siNB), were stained for E-
cadherin (red), and DAPI (blue). C. MCF7 cells transfected as in A and stained for E-cadherin (red), HA-fused proteins (green) and DAPI (blue). Arrows
indicate cell-cell contacts of transfected cells. D. MCF7 cells transfected with plasmids including vector pcDNA-GFP, pcDNA-GFP-NEDD9, pcDNA-GFP-
BCAR1, or pcDNA-GFP-NEDD9 and pcDNA-GFP-BCAR1 (green) were stained for b-catenin (red), and DAPI (blue). Arrowheads point to b-catenin
localization at the focal adhesions. Scale bar in B–D,2 0mm. E. Immunofluorescence demonstrating that b-catenin localizes to focal adhesions in
MCF7 cells expressing pcDNA-GFP-NEDD9 and pcDNA-GFP-BCAR1 (green). b-catenin (red) and the focal adhesion protein paxillin (blue) are indicated.
Scale bar, 20 mm. Bottom panel represents magnifications of indicated areas from boxes.
doi:10.1371/journal.pone.0022102.g002
Figure 3. Fractionation indicates Cas proteins decrease E-cadherin association with the insoluble fraction. MCF7 cells were transfected
as in Figure 2A and B, fractionated to insoluble (A) and soluble (B) fractions, and then analyzed for expression of E-cadherin. Graphs represent E-
cadherin normalized to b-actin in each fraction calculated from 3 independent experiments. Immunoblot represents a typical experiment. *, P,0.05,
**, P,0.01, ***, P,0.001. Error bars represent SE.
doi:10.1371/journal.pone.0022102.g003
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22102Figure 4. Cas proteins increase lysosomal colocalization of E-cadherin. A. Immunofluorescence assessing E-cadherin localization, with
lysosomes visualized with LAMP-1 (green) in cells overexpressing GFP-BCAR1 (B) and GFP-NEDD9 (N), indicated in blue, after treatment with
cloroquine. E-cadherin is shown in red. Scale bar, 20 mm. Arrows indicate colocalized E-cadherin and LAMP-1. B–E. Quantification of western analysis
and representative results of whole cell lysates prepared from MCF-7 cells transfected with either the vector pcDNA-GFP, pcDNA-HA-NEDD9 (N),
pcDNA-HA-BCAR1 (B), or pcDNA-HA-NEDD9 and pcDNA-HA-BCAR1 (NB), and treated with B. vehicle (DMSO), C. ammonium chloride (NH3Cl), D.
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heterogeneous (Figure 7B). By contrast, total levels of E-cadherin
and b-catenin in tumors were not grossly affected based on Nedd9
genotype (Figure 7C).
Discussion
This work for the first time establishes that Cas-dependent
signaling through SRC kinase promotes E-cadherin removal from
cell junctions and its lysosomal degradation in mammalian cells,
and suggests this relationship is retained in mammary tumors.
Surprisingly, this result differs from our findings in Drosophila,
where loss of Dcas increased the total levels of E-cadherin protein
in embryos and larvae [34], but the E-cadherin protein failed to
localize to the membrane. There are several plausible reasons for
the different findings. First, the evolutionary distance between
Drosophila and mammals may have resulted in different signaling
relationships between Cas proteins and E-cadherin. Second,
embryogenesis in the sustained absence of Dcas may lead to the
induction of compensatory mechanisms to upregulate levels of E-
cadherin in response to lost function at cell-cell contacts.
Supporting this latter idea, we observed that in mammals, the
inverse relationship between Cas expression and total levels of E-
cadherin was more notable following transient manipulations of
Cas proteins (Figure 1), rather than in the context of the sustained
loss of Nedd9 in mammary tumor development (Figure 7),
although the failure of E-cadherin to associate with cell junctions
and the detergent insoluble (membrane- and cytoskeleton-
enriched) cell fraction was observed in all cases. Third, in
Drosophila, the greatest effect on E-cadherin expression was
observed when both Dcas and its interacting partner FAK were
absent, while this study only examined inhibition of Cas proteins.
It is possible that dual inhibition of FAK and Dcas might yield a
qualitatively different result regarding E-cadherin expression.
However, we view this as unlikely, as we already have reported
that FAK activation levels are significantly depressed in Nedd9
2/2
versus Nedd9
+/+ tumors [22].
Intriguingly, our data show that in cells overexpressing Cas
proteins, part of the intracellular pool of b-catenin colocalized with
the Cas proteins at focal adhesions (Figure 2). A prior report found
direct interactions between b-catenin and the focal adhesion-
associated protein paxillin was induced under some cell growth
conditions, such as response to injury [42]. It is possible that
NEDD9 and BCAR1 overexpression provides similar stimuli,
indirectly affecting b-catenin recruitment. Alternatively, an NMR
spectroscopic study of BCAR1 identified a domain within this
protein that formed a four-helix bundle similar to that found in
other proteins such as a-catenin, involved in protein-protein
interactions [43], that might serve to directly recruit b-catenin to
an anomalous location. At present, the functional significance of
this relocalization is unknown in the context of Cas-associated
tumorigenesis; this topic requires further study.
It is interesting that NEDD9 and BCAR1 regulation of E-
cadherin are not equally inhibited by Y-27632, an inhibitor of
p160ROCK. We have previously shown that NEDD9 interacts
with the Rho-GEF ECT2 to regulate Rho and p160ROCK
activity during mitosis [32]. Reciprocally, Ando et al have found
that inhibition of RhoA GTPases and p160ROCK influences the
localization and phosphorylation of NEDD9 [44]. No such direct
connections have as yet been identified for BCAR1, raising the
possibility that NEDD9 may be more active than BCAR1 in its
ability to signal through a Rho-p160ROCK effector interaction in
interphase, as in mitotic cells.
This study is in general agreement with the recent work by Bui
et al. that showed a role for NEDD9 in mediating dioxin-induced
EMT [28]. In that study, knockdown of NEDD9 restored a
dioxin-induced reduction in E-cadherin expression, while dioxin
treatment strongly induced the expression of NEDD9. Although a
role for SRC was not examined in that work, SRC has been
shown by others to be similarly induced by dioxin, and to directly
bind to the aryl hydrocarbon receptor through which dioxin acts
[45], suggesting a similar response module is involved in a very
different model for tumor cell invasiveness. Taken in sum, these
data support the idea that the upregulation of Cas proteins in a
subset of tumors promotes tissue invasion in part by removing E-
cadherin from the cell surface, and hence disrupting cell-cell
junctions.
Materials and Methods
Transfection and RT-PCR
MCF-7 breast adenocarcinoma cells were transfected with
20 nM non-targeting scrambled siRNA, or siRNAs to NEDD9
(Hs_NEDD9_2), BCAR1 (Hs_BCAR1_6), or both (Qiagen,
Valencia, CA), with RNAiMAX transfection reagent (Invitrogen,
Carlsbad, CA). pcDNA3.1-based plasmids containing HA- or GFP
fused NEDD9 or BCAR1 were nucleofected into MCF-7 cells
using Amaxa V kit (Amaxa, Walkersville, MD). siRNA or plasmid
sequences are available on request. mRNA was isolated using
RNeasy Mini Kit (Quigen, Valencia, CA). Real-time RT-PCR
was performed by the Fox Chase Cancer Center Genomics
Facility, using approaches previously described [7]. The probes
and primers for E-cadherin and the catenins are available upon
request.
Fractionation and western analysis
For fractionation, cells were lysed in CSK buffer [35] containing
0.5% Triton-X100, incubated 15 min on ice, harvested by
scraping and passed 4 times through a 26.5G needle, and then
centrifuged for 1 hour at 14,000 g at 4uC. Pellets were solubilized
in 3X Laemmli sample buffer containing 10% SDS, then boiled
for 20 min. Whole cell lysates were prepared by scaping cells off
plates in 3X Laemmli sample buffer containing 10% SDS, and
boiling for 20 minutes. Solubilized pellets prepared from 10
5 cells,
and whole cell lysate equivalent to 5610
5 cells were used for
analysis. Samples were run on 10% Bis-Tris NuPage PAGE
(Invitrogen, Carlsbad, CA). Western blots were performed using
standard protocols, and signals visualized either by film or by
Odyssey (LICOR, Lincoln, NE). Signals in the linear range
obtained from western blots were quantitated with Odyssey
software, or alternatively with ImageJ software. Significance of
data was analyzed by a two-tailed paired-sample t-test in MS
Excel.
For drug inhibition experiments, cells were cultured in medium
with 1 mM Y-27632 (Calbiochem, San Diego, CA), 25 nM
dasatinib (Bristol-Myers Squibb, New York, NY), or 20 nM PP2
(Calbiochem, San Diego, CA) 24 hours post-transfection, and cells
monensin or E. chloroquine, to inhibit lysosomal action. Graphs represents total levels of E-cadherin normalized to b-actin, calculated from more than
4 independent experiments. P values were calculated to compare levels of E-cadherin in vector-transfected cells versus cells transfected with NEDD9,
BCAR1 or both within each drug treatment group; *, P,0.05, **, P,0.01, n.s., non-significant. Error bars represent SE.
doi:10.1371/journal.pone.0022102.g004
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22102Figure 5. Cas proteins activate SRC to downregulate E-cadherin expression. A, B. Western analysis (A) of whole cell lysates prepared from
MCF-7 cells overexpressing pcDNA vector alone (-), or HA-tagged BCAR1 (B), NEDD9 (N), or both (NB), and treated with dasatinib versus vehicle.
Quantification of results comparing levels of E-cadherin, normalized to b-actin, within treated and, separately, untreated groups from 4 independent
experiments, is also shown (B). Src Y
416 phosphorylation reflects activity state of kinase. P values reflect the difference between the vehicle and drug
treatment condition, for each transfected protein indicated; *, P,0.01, **, P,0.001, ns, non-significant. C. Experiment as in A performed with PP2.
Note, SRC inhibition was not as complete as in A in these experiments, because at higher PP2 concentrations extensive cell death was observed,
probably due to the broader spectrum of PP2 versus dasatinib targets. D, E. Experiment as in A, B, but in cells treated with Y27632 versus vehicle.
Phosphorylation of the downstream p160ROCK target MYPT1 was assessed in parallel to confirm complete inhibition of p160ROCK (not shown).
*, P,0.001, **, P,0.01 ***, P,0.0001, ns, non-significant. Error bars represent SE.
doi:10.1371/journal.pone.0022102.g005
NEDD9 and BCAR1 Negatively Regulate E-Cadherin
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22102were harvested 24 hours later for western blot analysis and RhoA
activation assay, using a kit from Cytoskeleton, Inc. (Denver, CO).
Inhibition of lysosome activity was achieved by treatment of cells
for 24 hours prior to analysis with 2 mM ammonium chloride
(Sigma-Aldrich, St. Louis, MO), 10 mM monensin (Calbiochem,
San Diego, CA), or 50 mM chloroquine (Sigma-Aldrich, St. Louis,
MO).
Immunofluorescence
MCF7 cells grown on cover slips were washed twice with PBS,
incubated in 4% PFA for 20 min, rinsed with PBS and
permeabilized in 0.1% Triton X-100 solution for 20 min at room
temperature. Samples were blocked with 1% BSA for 1 hour and
incubated with primary antibody for 2 hours. Samples were
washed and incubated for 1 hour with secondary antibody
conjugated with Alexafluor 488, 568 or 633 (Molecular Probes
Inc., Eugene, OR) diluted at 1:1000. Cover slips were mounted
onto glass slides in ProLong Gold antifade reagent containing
nuclear stain (Invitrogen, Carlsbad, CA) and visualized using a
Nikon C1 confocal microscope. Images were analyzed using
Metamorph software (Molecular Devices, Sunnyvale, CA).
Primary antibodies used included mouse anti-E-cadherin
ECCD-2 (Invitrogen, Carlsbad, CA), mouse anti-E-cadherin,
rabbit anti-b-catenin ab6302 (Abcam, Cambridge, MA), and
anti-b-actin ab6276 (HRP conjugated, Abcam, Cambridge, MA),
or anti-b-actin (clone AC-15, Sigma-Aldrich, St. Louis, MO).
Secondary antibodies included HRP-conjugated anti-mouse or -
rabbit (Amersham, Pittsburgh, PA), IRDye800 or 700-conjugated
a-mouse, -rat or –rabbit (LICOR, Lincoln, NE). Low to moderate
intensity images were used for quantification of assays, to ensure
linearity of signal in immunoblots related to measurement of levels
of E-cadherin and b-actin.
Immunohistochemistry
The derivation and preparation of the MMTV-PyVT mam-
mary tissues for immunohistochemistry has been described in
detail [22]. Briefly, a standard two-stage indirect immunoperox-
idase staining protocol was used for all tissues (Histostain-Plus Kit,
Invitrogen, Carlsbad, CA). Citrate based antigen retrieval buffer
was from BD Biosciences, San Jose, CA). As controls, sections
were stained with a control rabbit IgG or diluent alone (5% goat
serum in Tris-buffered saline). All tissue sections were incubated at
room temperature for 1 h with primary antibodies and 30 minutes
with secondary antibody solution; these and subsequent proce-
dures were performed according to the instructions provided with
the kit. Sections were counterstained with hematoxylin (Sigma, St
Louis, MO). Rabbit antibodies to E-cadherin (ab53033) and b-
catenin (ab6302) from Abcam (Cambridge, MA) were used at a
dilution of 1:100. Images were acquired at 40x with a Nikon
Eclipse E600 microscope.
Figure 6. Treatment with SRC inhibitors reverses CAS-induced downregulation of E-cadherin. Immunofluorescence of MCF7 cells
expressing vector pcDNA-GFP, pcDNA-GFP-NEDD9, pcDNA-GFP-BCAR1, or pcDNA-GFP-NEDD9 and pcDNA-GFP-BCAR1 (transfected cells shown in
green) and treated with vehicle or PP2. Arrows indicate presence of E-cadherin (shown in red) at cell junctions in dasatinib or PP2-treated cells
expressing vector, BCAR1 and/or NEDD9, but absence of E-cadherin in similarly transfected cells treated with vehicle. Scale bar, 20 mm.
doi:10.1371/journal.pone.0022102.g006
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2/2 mammary tumors have increased E-cadherin at cell junctions. A, B. Immunohistochemical evaluation of MMTV-
PyVT;Nedd9
2/2 and MMTV-PyVT Nedd9
+/+ mammary tumors for E-cadherin (A) and b-catenin (B) protein expression and localization. Insets (thick
lines) are magnifications of indicated areas (thin lines). Three representative independently arising tumors are shown for each genotype. Scale bar,
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